CompaniesAdverum Biotechnologies
Adverum Biotechnologies logo

Adverum Biotechnologies

active
Redwood City, CA, United States
Founded 2006
Website
About

Adeno-Associated Virus Delivery, Gene Therapy

Areas of Focus

Categories

Virus TechnologyGene Therapy, RNA & Peptide TherapyStem Cell & Cellular TherapyDrug Delivery & FormulationBiotech
Team (4)
Audit Committee
Audit Committee
Adverum Biotechnologies
team_member
Compensation Committee
Compensation Committee
Adverum Biotechnologies
team_member
Industry Leaders & Pioneers
Industry Leaders & Pioneers
Leadership Team
Adverum Biotechnologies
team_member
Research & Development Committee
Research & Development Committee
Adverum Biotechnologies
team_member
Clinical Trials (10)
View all

Total Trials

10

As Lead Sponsor

9

As Collaborator

1

Total Enrollment

556

By Phase

PHASE3: 1PHASE2: 2PHASE1: 1PHASE1/PHASE2: 2NA: 1

By Status

COMPLETED: 6ACTIVE_NOT_RECRUITING: 3RECRUITING: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
NCT01494805
NCT03748784
NCT04645212
NCT05607810
NCT05536973
NCT06856577
Hover over trial bars to see details

Recent Trials

NCT06856577Lead Sponsor
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
PHASE3Recruiting
284 participants
Started: Feb 28, 2025 · Completed: Mar 25, 2030
NCT05536973Lead Sponsor
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
PHASE2Active, not recruiting
69 participants
Started: Aug 23, 2022 · Completed: Aug 31, 2028
NCT05607810Lead Sponsor
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
N/AActive, not recruiting
22 participants
Started: Aug 10, 2022 · Completed: Apr 30, 2026
NCT04645212Lead Sponsor
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
N/AActive, not recruiting
23 participants
Started: Dec 14, 2020 · Completed: Jun 30, 2025
NCT04418427Lead Sponsor
ADVM-022 Intravitreal Gene Therapy for DME
PHASE2Completed
36 participants
Started: May 28, 2020 · Completed: Jun 14, 2023
View all 10 trials →
Funding History (20)
8-K
Sep 22, 2025
Filing
8-K
Aug 12, 2025
Filing
8-K
Jun 18, 2025
Filing
DEFA14A
May 23, 2025
Filing
8-K
May 14, 2025
Filing
DEFA14A
Apr 28, 2025
Filing
DEF 14A
Apr 28, 2025
Filing
8-K
Apr 15, 2025
Filing
8-K
Mar 31, 2025
Filing
8-K
Nov 18, 2024
Filing
Locations (1)
Headquarters
Redwood City, CA, United States
Map

Loading map...